학술논문
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Document Type
Article
Author
Source
Subject
*CLINICAL trials
*PULMONARY fibrosis treatment
*ANTI-inflammatory agents
*CLINICAL medicine research
*DRUG efficacy
*
*
*
*
Language
ISSN
0140-6736
Abstract
The article presents two randomized studies on the use of a novel antifibrotic and anti-inflammatory drug, pirfenidone, which reduces deterioration in lung function, in patients with idiopathic pulmonary fibrosis (IPF). Patients with IPF were assigned in a 1:1 ratio and 2:1:2 ratio to 2403 milligrams of pirfenidone per day. Based on results, it was observed that perfenidone offers favorable benefit risk profile and is a good treatment option for IPF.